in this article, we explain how this programme brought about the discovery and continuing progress of Glivec (Gleevec in The usa), the primary selective tyrosine-kinase inhibitor being permitted for the cure of the most cancers. 急性腎障害があらわれることがあるので、投与開始前及び投与中に定期的に腎機能検査を